Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Overview | 9 | 1 |
| Therapeutics Development | 10 | 3 |
| Human Papilloma Virus (HPV) E7 Protein Products under Development by Stage of Development | 10 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Products under Development by Therapy Area | 11 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Products under Development by Indication | 12 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Products under Development by Companies | 15 | 3 |
| Human Papilloma Virus (HPV) E7 Protein Products under Development by Universities/Institutes | 18 | 2 |
| Human Papilloma Virus (HPV) E7 Protein Therapeutics Assessment | 20 | 5 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Human Papilloma Virus (HPV) E7 Protein Companies Involved in Therapeutics Development | 25 | 16 |
| Advaxis, Inc. | 25 | 1 |
| AnGes MG, Inc. | 26 | 1 |
| Cancer Research Technology Limited | 27 | 1 |
| Etubics Corporation | 28 | 1 |
| Formune S.L. | 29 | 1 |
| Genexine, Inc. | 30 | 1 |
| Genticel S.A. | 31 | 1 |
| iBio, Inc. | 32 | 1 |
| Immunovaccine, Inc. | 33 | 1 |
| Inovio Pharmaceuticals, Inc. | 34 | 1 |
| Kite Pharma, Inc. | 35 | 1 |
| MedImmune, LLC | 36 | 1 |
| Selecta Biosciences, Inc. | 37 | 1 |
| Tomegavax, Inc. | 38 | 1 |
| Transgene SA | 39 | 1 |
| VLPbio | 40 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Drug Profiles | 41 | 47 |
| Antibodies to Target E7 for HPV Associated Cancer Drug Profile | 41 | 1 |
| Aptamer to Target HPV E7 Protein for Cervical Cancer Drug Profile | 42 | 1 |
| axalimogene filolisbac Drug Profile | 43 | 15 |
| BLSILSB-710c Drug Profile | 58 | 1 |
| Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer Drug Profile | 59 | 2 |
| CerviVax Drug Profile | 61 | 1 |
| DPXE-7 Drug Profile | 62 | 1 |
| EDA-HPVE7 Drug Profile | 63 | 1 |
| ETBX-041 Drug Profile | 64 | 1 |
| GLBL-101c Drug Profile | 65 | 2 |
| GTL-001 Drug Profile | 67 | 3 |
| GTL-002 Drug Profile | 70 | 1 |
| GX-188E Drug Profile | 71 | 1 |
| human papillomavirus [Serotype 16] vaccine Drug Profile | 72 | 1 |
| human papillomavirus vaccine Drug Profile | 73 | 1 |
| INO-3106 Drug Profile | 74 | 1 |
| INO-3112 Drug Profile | 75 | 2 |
| PVX-01 Drug Profile | 77 | 1 |
| SEL-701 Drug Profile | 78 | 1 |
| TA-CIN Drug Profile | 79 | 1 |
| TG-4001 Drug Profile | 80 | 2 |
| Vaccine for Cervical Cancer Drug Profile | 82 | 1 |
| Vaccine to Target HPV E7 Protein for Cervical Cancer Drug Profile | 83 | 1 |
| VGX-3100 Drug Profile | 84 | 3 |
| Vvax-001 Drug Profile | 87 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Dormant Projects | 88 | 2 |
| Human Papilloma Virus (HPV) E7 Protein Discontinued Products | 90 | 1 |
| Human Papilloma Virus (HPV) E7 Protein Featured News &Press Releases | 91 | 12 |
| Jun 15, 2016: Genticel to Present Clinical Results of GTL001 at EUROGIN 2016 Congress in Salzburg, Austria | 91 | 1 |
| Jun 15, 2016: Genticel to Present Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria | 91 | 1 |
| Jun 13, 2016: Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001 | 91 | 1 |
| Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer | 92 | 1 |
| Jun 06, 2016: Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports | 93 | 1 |
| Jun 01, 2016: Genticel Announces Publication in Clinical Cancer Research of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001 | 94 | 1 |
| Apr 25, 2016: Phase II Cervical Cancer Study with Advaxis Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting | 95 | 1 |
| Apr 20, 2016: Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001 | 96 | 1 |
| Apr 20, 2016: New Preclinical Study Shows Immunovaccine s DepoVax-based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors | 97 | 1 |
| Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company s Lm Technology Platform | 98 | 1 |
| Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as Best Therapeutic Vaccine by World Vaccine Congress | 99 | 1 |
| Mar 29, 2016: Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort | 100 | 1 |
| Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan | 101 | 1 |
| Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract | 101 | 1 |
| Mar 07, 2016: Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer | 102 | 1 |
| Appendix | 103 | 2 |
| Methodology | 103 | 1 |
| Coverage | 103 | 1 |
| Secondary Research | 103 | 1 |
| Primary Research | 103 | 1 |
| Expert Panel Validation | 103 | 1 |
| Contact Us | 103 | 1 |
| Disclaimer | 104 | 1 |